Eli Lilly and Company

(New York Stock Exchange)

Eli Lilly and Company (LLY) stock at a glance

Full Eli Lilly and Company report
Ticker
LLY
Exchange
New York Stock Exchange
News sentiment Β· last 30 days
+54 Bullish β–Ό -6 vs. previous 30 days
30-day average of 11 articles Β· scale βˆ’100 to +100

Across 11 scored articles from Oct 16 to Nov 14, 2026 (UTC), the average sentiment of Eli Lilly and Company news is Bullish (+54) on a scale from βˆ’100 to +100. That is down 6 points from the previous 30 days (+60).

+75 Bullish 1 article

Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.

Articles

50
Show Summary
Show Bulletpoints
Detailed View
Bullish +65

Should You Buy Eli Lilly Stock Now or Wait for a Dip? - AOL.com

AI-generated analysis

Eli Lilly (NYSE: LLY) has reached a $1 trillion market cap, driven by its dominant position in the GLP-1 weight loss market with products like Mounjaro and Zepbound. While the stock is up modestly this year, it has delivered over 400% returns over the last five years. However, the company currently trades at a premium valuation of 40 times trailing earnings, raising questions about whether investors should buy now or wait for a potential price dip. The article highlights Lilly's strong long-term growth prospects supported by its deep financial reserves and strategic acquisitions in healthcare, including Orna Therapeutics and recent infectious disease portfolio expansions. Net income has surged to $25.3 billion in the trailing 12 months, reflecting a massive increase from just a few years ago. Management is described as growth-oriented, positioning the company for continued expansion beyond its current blockbuster drugs. Despite the high valuation, the author argues that paying a premium is justified by the company's promising upside and long-term business trajectory. The stock may face short-term volatility due to market conditions or healthcare reform concerns, but the outlook remains positive for long-term holders committed to a five-plus-year horizon. The piece concludes by noting that while Stock Advisor recently excluded Lilly from its top 10 list, the company remains a compelling investment for patient capital.

πŸ“ˆ Market cap hits $1 trillion driven by GLP-1 success.

πŸ’° Net income reaches $25.3 billion in trailing 12 months.

πŸ”¬ Expanding via acquisitions like Orna Therapeutics for RNA.

βš–οΈ Stock trades at premium 40x earnings valuation.

πŸ“‰ Shares delivered over 400% returns in last five years.

πŸ“ˆ Eli Lilly's market cap has reached $1 trillion, driven by strong performance in the GLP-1 weight loss market.

πŸ’° The company reported net income of $25.3 billion in the trailing 12 months, a significant increase from previous years.

πŸ”¬ Lilly is expanding its operations through strategic acquisitions, including Orna Therapeutics for RNA therapies and recent infectious disease portfolio additions.

βš–οΈ The stock currently trades at a premium valuation of 40 times its trailing earnings, which the article notes is not cheap.

πŸ“‰ Over the last five years, Eli Lilly shares have delivered returns exceeding 400% for investors.

🧬 The company is in the early innings of growth for its GLP-1 products Mounjaro and Zepbound, which are already generating billions in sales.

πŸ›‘οΈ Management is characterized as having a growth-oriented nature with a diverse operational portfolio supporting future expansion.

⏳ Analysts suggest that while the stock may fluctuate short-term due to market conditions, it remains an excellent long-term investment for five-plus year horizons.

πŸ“Š The article notes that Eli Lilly was excluded from The Motley Fool's recent top 10 Stock Advisor list, though the company maintains a bullish stance on its own prospects.

Bullish Signals
  • Market cap hit $1 trillion with 400% five-year returns.
  • Net income reached $25.3 billion in trailing 12 months.
  • Expanding pipeline via Orna Therapeutics and infectious disease deals.
  • GLP-1 products generate billions with massive future growth potential.
  • Deep financial pockets enable continued investment in growth.
  • Growth-oriented management focuses on long-term prospects.
Risk Factors
  • Premium valuation at 40x trailing earnings.
  • Potential short-term volatility from market conditions.
Bullish Signals
  • Eli Lilly has achieved a $1 trillion market cap and delivered over 400% returns over the past five years.
  • The company's net income reached $25.3 billion in the trailing 12 months, demonstrating massive profitability growth.
  • Lilly is successfully expanding its pipeline through acquisitions like Orna Therapeutics and recent infectious disease portfolio additions.
  • GLP-1 products Mounjaro and Zepbound are already generating billions in sales with significant future growth potential remaining.
  • The company possesses deep financial pockets that enable continued investment in future growth initiatives.
  • Management is described as growth-oriented, focusing on long-term prospects rather than short-term fluctuations.
Risk Factors
  • Eli Lilly trades at a premium valuation of 40 times trailing earnings, which the article explicitly describes as not cheap.
  • The stock faces potential short-term volatility due to broader market conditions and concerns regarding healthcare reform.
Bullish +60

Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy

AI-generated analysis

Eli Lilly and Novo Nordisk reported divergent Q1 2026 results that highlight a shifting landscape in the obesity drug market. Eli Lilly grew revenue by 55.5% and raised guidance, driven primarily by tirzepatide products Mounjaro and Zepbound, which saw significant year-over-year growth fueled by international expansion and China's NRDL inclusion. In contrast, Novo Nordisk reported a 4% adjusted sales decline at constant currency, prompting the company to announce plans to cut 9,000 jobs as it consolidates its franchise around semaglutide. Lilly's strategy involves aggressive growth through both organic expansion and acquisitions in cell therapy and other biology areas. The company successfully launched Foundayo, the first GLP-1 pill without food or water restrictions, while managing a deliberate trade where volume jumped 65% despite a 13% drop in realized prices. Conversely, Novo is facing headwinds with its injectable Wegovy growing only 12% while oral products like Ozempic and Rybelsus declined, leading to a restructuring effort that includes absorbing the Most Favoured Nations pricing deal. The article concludes by comparing the two companies' strategic positions for the future. Lilly is viewed as the cleaner business with strong offense-mode execution, reflected in its stock price surge, though its valuation is high. Novo presents a potential turnaround story with a gross margin of 81% and a new oral semaglutide product, but faces risks from upcoming Medicare coverage changes and planned list price cuts in January 2027 that could pressure margins.

πŸ“ˆ Eli Lilly Q1 2026 revenue surged 55.5% with EPS guidance raised to $35.5-$37.

πŸ’Š Mounjaro revenue hit $8.66 billion, up 125%, while Zepbound added $4.16 billion.

πŸ“‰ Novo Nordisk sales fell 4% and plans to cut 9,000 jobs amid Ozempic decline.

πŸ’Š Foundayo FDA approved as only GLP-1 pill with no food or water restrictions.

πŸš€ Lilly acquired Orna, Centessa, Kelonia, and Ajax to expand cell therapy portfolios.

πŸ“ˆ Eli Lilly reported Q1 2026 revenue growth of 55.5% and raised non-GAAP EPS guidance to $35.5-$37.

πŸ’Š Mounjaro generated $8.66 billion in revenue, up 125% year over year, while Zepbound added $4.16 billion.

πŸ“‰ Novo Nordisk posted a 4% adjusted sales decline at constant currency and announced plans to cut 9,000 jobs.

πŸ’Š Foundayo received FDA approval as the only GLP-1 pill with no food or water restrictions.

πŸš€ Lilly announced acquisitions of Orna, Centessa, Kelonia, and Ajax to expand into cell therapy and other biology areas.

πŸ“‰ Novo's Ozempic sales slid 8% in the US, while Rybelsus dropped 15% globally.

πŸ’Š Novo's new Wegovy pill launched on January 5, 2026, booked $2.26 billion with over 1 million patients.

πŸ“‰ The CagriSema REDEFINE 4 trial missed its primary endpoint despite achieving 23% weight loss.

πŸ’Έ A planned 50% Wegovy list price cut in January 2027 is expected to pressure Novo's margins.

πŸ₯ Medicare Part D coverage for obesity drugs begins July 1, 2026, potentially offsetting future price cuts for Novo.

πŸ“ˆ Eli Lilly's stock has risen 48.98% over the past year reflecting bullish investor sentiment.

πŸ“‰ Novo Nordisk shares are down 41.53% over the past year and 14.22% year to date.

Bullish Signals
  • Revenue grew 55.5% in Q1 2026.
  • Mounjaro revenue surged 125% to $8.66 billion.
  • Zepbound revenue increased 80% to $4.16 billion.
  • International revenue climbed 81%.
  • Stock price rose 48.98% over the past year.
Risk Factors
  • Novo Nordisk adjusted sales declined 4% at constant currency.
  • Novo cutting 9,000 jobs due to declining sales.
  • Ozempic US sales fell 11%, Rybelsus dropped 15%.
  • CagriSema REDEFINE 4 trial missed primary endpoint.
  • Wegovy price cut in Jan 2027 pressures margins.
Bullish Signals
  • Eli Lilly grew revenue by 55.5% in Q1 2026, demonstrating strong momentum in its obesity franchise.
  • Lilly raised its non-GAAP EPS guidance to $35.5-$37, indicating confidence in future performance.
  • Mounjaro revenue surged 125% year over year to $8.66 billion, driven by international launches and China's NRDL inclusion.
  • Zepbound revenue increased 80% to $4.16 billion, showing robust growth in the weight-loss category.
  • Lilly successfully executed a volume-driven strategy with a 65% jump in volume despite lower realized prices.
  • Foundayo was approved by the FDA as the only GLP-1 pill without food or water restrictions, offering a unique market advantage.
  • Lilly's international revenue climbed 81%, suggesting significant global expansion potential.
  • Acquisitions in cell therapy and sleep-wake biology indicate a diversified growth strategy beyond current obesity drugs.
  • Ebglyss revenue jumped 141% and Jaypirka rose 79%, highlighting success in other therapeutic areas.
  • Lilly's stock price increased 48.98% over the past year, reflecting strong market confidence.
Risk Factors
  • Novo Nordisk reported a 4% adjusted sales decline at constant currency, signaling weakness in its core franchise.
  • Novo is cutting 9,000 jobs as part of a restructuring effort to address declining sales and portfolio fragmentation.
  • Ozempic US sales fell 11%, while Rybelsus dropped 15%, indicating challenges in the oral semaglutide segment.
  • The CagriSema REDEFINE 4 trial missed its primary endpoint, denting the next-generation drug thesis for Novo.
  • A planned 50% Wegovy list price cut in January 2027 will likely pressure Novo's gross margins significantly.
  • Novo Nordisk shares are down 41.53% over the past year and 14.22% year to date, reflecting investor concerns.
  • Lilly's high valuation means any stumble with Foundayo or other products could lead to a sharp stock correction.
Bullish +75

Eli Lilly is on pace for its first record close of 2026

AI-generated analysis

Eli Lilly (LLY) shares rose approximately 3.7% on Thursday, trading near $1,123 per share. If this price level is maintained, the company would achieve its first record closing stock price for the year 2026, surpassing the previous high of $1,109.94 set on November 25 of the prior year. The stock's increase was driven by news that CVS Health has restored coverage for Eli Lilly's weight-loss medication, Zepbound. This positive development follows a strong month for the pharmaceutical giant, during which its shares have gained roughly 22.3% from the start of the year to date.

πŸ“ˆ Shares rose 3.7% to trade near $1,123.

🎯 Stock on track for first 2026 record high.

πŸ’Š CVS restored Zepbound coverage, boosting investor sentiment.

πŸ“… Stock gained 22.3% year-to-date this strong month.

πŸ“ˆ Eli Lilly shares rose 3.7% on Thursday, trading near $1,123 per share.

🎯 If this price level holds, the company is on track for its first record closing stock price of 2026.

πŸ“‰ The previous record high was set on November 25 last year at $1,109.94 per share.

πŸ’Š CVS Health restored coverage for Eli Lilly's weight-loss drug Zepbound, boosting investor sentiment.

πŸ“… This rally adds to a strong month for the stock, which has gained approximately 22.3% year-to-date.

Risk Factors
  • Stock trades at $1,123, a premium over last year's record.
  • Shares up 22.3% MTD suggest gains driven by sentiment.
Risk Factors
  • Eli Lilly's stock is trading around $1,123, which represents a significant premium over the previous record close of $1,109.94 on Nov. 25 of last year, potentially indicating an unsustainable valuation.
  • The company's shares are up roughly 22.3% month to date, suggesting that recent gains may be driven by short-term sentiment rather than fundamental improvements in earnings or revenue growth.
Bullish +75

Cramer says Apple and Eli Lilly still have room to run after post-earnings rallies

AI-generated analysis

Jim Cramer highlighted on Friday that both Apple and Eli Lilly still possess significant upside potential following their recent post-earnings rallies. The S&P 500 reached a fresh intra-day high, driven largely by gains in Apple, which is part of the "Mag Seven" comeback according to Cramer. On Thursday, Apple reported a near-perfect quarter with second-quarter revenue rising 17% to $111.2 billion, surpassing the LSEG estimate of $109.7 billion. The company also issued strong guidance, noting that its installed base of active devices has reached an all-time high exceeding 2.5 billion across all product categories and geographic areas. Cramer advised investors to hold Apple rather than trade it, describing the earnings call as a source of "pure joy." He specifically recommended against selling Eli Lilly after its shares jumped another 3% following a nearly 10% rally on Thursday. Cramer characterized Lilly's quarter as "extraordinary," citing massive top and bottom-line beats where revenue surged 56% year-over-year to $19.8 billion. He stated, "If you sell Lilly, you're going to be selling it too soon, no matter what you do." In terms of market context, while Meta and Microsoft also reported earnings beats on Wednesday, they did not secure the same investor enthusiasm as Apple and Amazon, which had beaten expectations the previous day. Additionally, oil prices were noted to have fallen following news that Iran reportedly responded to Pakistani mediators with an updated peace proposal. Jim Cramer's Charitable Trust maintains long positions in various Club holdings including LLY, GOOGL, META, MSFT, APPL, and AMZN. He follows specific protocols for trading within his charitable trust, waiting 45 minutes after sending a trade alert before executing any buy or sell order for Apple and Eli Lilly. If a stock is discussed on CNBC television, Cramer adheres to a 72-hour waiting period between issuing a trade alert and executing the trade. These disclosures come with standard terms and conditions noting that no fiduciary obligation exists and no specific profit outcome is guaranteed for subscribers receiving trade alerts via the CNBC Investing Club.

πŸ“ˆ S&P 500 hit new highs driven by Apple's revenue beat and device record.

πŸ’° Eli Lilly surged 3% after reporting a massive 56% revenue jump.

⚠️ Cramer advises holding strong tech like Apple while avoiding premature Eli Lilly sales.

πŸ€– His trust follows strict delays: 45 minutes post-alert or 72 hours for TV mentions.

πŸ“ˆ The S&P 500 reached a new intraday high on Friday, driven primarily by strong gains in Apple shares.

πŸ’° Apple's second-quarter revenue rose 17% to $111.2 billion, surpassing analyst estimates of $109.7 billion.

πŸ”„ Jim Cramer described the market rally as "the comeback of the Mag Seven" following recent positive earnings from Amazon and Alphabet.

πŸ“± Apple reported an all-time high in its installed base of active devices across all categories and geographies, exceeding 2.5 billion units.

πŸ’¬ Cramer advised investors to "own" Apple stock rather than trade it after praising the company's earnings call as bringing him "pure joy".

⬆️ Shares of Eli Lilly rose another 3% on Friday following a significant post-earnings rally from Thursday's session.

πŸ§ͺ Eli Lilly reported an extraordinary quarter with revenue surging 56% year-over-year to $19.8 billion, beating top and bottom-line estimates.

⚠️ Cramer warned investors against selling Eli Lilly too soon despite the recent price increase, calling the move risky if executed now.

πŸ›οΈ The CNBC Investing Club is long on both Apple (APPL) and Eli Lilly (LLY), among other major tech and healthcare stocks.

πŸ€– Cramer's charitable trust follows a strict waiting period of 45 minutes after issuing trade alerts before executing any buy or sell orders.

πŸ“° If Cramer discusses a stock on CNBC TV, his trust waits an additional 72 hours after the alert before acting on it.

β›½ Oil prices fell on Friday as Iran reportedly shared an updated peace proposal to mediators in Pakistan.

πŸ•ŠοΈ Hope for a potential agreement between Iran and the US to end the war sparked the decline in energy commodity prices.

πŸ“… This recap covers key moments from Friday's "Morning Meeting" livestream held at 10:20 a.m. ET with Jim Cramer.

πŸ“‰ Meta and Microsoft reported earnings beats on Wednesday but failed to generate the same investor enthusiasm as Apple.

Bullish Signals
  • Eli Lilly saw an extraordinary quarter with revenue surging 56% year-over-year to $19.8 billion, representing massive top and bottom-line beats.
  • Shares of Eli Lilly jumped another 3% following a nearly 10% post-earnings rally, demonstrating continued strong investor confidence.
  • Jim Cramer emphasized that the stock has 'lots of room to run' and advised investors not to sell too soon, noting the exceptional performance.
  • The CNBC Investing Club holds positions in Eli Lilly (LLY), signaling bullish sentiment from Jim Cramer based on recent results.
Risk Factors
  • The article relies heavily on optimistic commentary from Jim Cramer regarding Apple and Eli Lilly without addressing any potential downside risks or valuation concerns.
  • Jim Cramer explicitly advises investors to 'own' Apple rather than 'trade it', which may discourage profit-taking in a potentially overvalued market after recent rallies.
  • Despite the positive earnings, Meta and Microsoft reported beats that failed to win over investors, indicating broader market skepticism towards Big Tech valuations.
  • The article includes standard investment disclaimers stating that no profit is guaranteed and no fiduciary duty exists, which serves as a risk warning for investors following Cramer's advice.
  • Cramer's charitable trust holds positions in several tech giants (GOOGL, META, MSFT) mentioned with mixed performance, suggesting concentration risk in the sector.
Somewhat Bearish -35

Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%

AI-generated analysis

On CNBC's Fast Money panel, there was a significant shift in perspective regarding two major biotechnology companies, Novo Nordisk (NVO) and Eli Lilly (LLY), suggesting that Novo Nordisk has become more appealing to investors. This change in sentiment follows a substantial decline for Novo Nordisk, which fell approximately 68% from its mid-2024 highs near $127 to recent levels around $40. The panel highlighted that while Eli Lilly has historically outperformed significantlyβ€”turning $1 into $2.30 over the past three years versus Novo's $1 to $0.48β€”the convergence of their stock prices and divergent valuations are reshaping the investment landscape. A key driver for this re-evaluation was early data released on Eli Lilly's newly approved oral GLP-1 medication, Fendayo. In its second week of sales, the drug attracted roughly 3,700 prescriptions, which stood in stark contrast to Novo Nordisk's competing oral offering that garnered over 18,000 prescriptions in a similar timeframe. This significant gap in prescription uptake for Lilly’s new product provided ammunition for investors seeking value in the GLP-1 space. In contrast, Eli Lilly reported strong financial results in Q1 2026 with revenue of $19.8 billion and EPS of $8.55, along with raised guidance for full-year revenue between $82.0 billion and $85.0 billion. Valuation metrics further underscore the panel's argument that Novo Nordisk now offers a more compelling setup. Novo trades at approximately 12 times earnings compared to Eli Lilly's 26 times earnings, with some projections indicating even higher multiples like 38x for Lilly. Additionally, Novo Nordisk presents attractive income characteristics with a projected free cash flow yield of 6.5% in 2027 and a dividend yield near 4%. Conversely, despite its high growth trajectory, Lilly's stock faces pressure due to these premium multiples and the weaker initial commercial performance of its new oral formulation. Some panelists characterized Novo as a "get paid to wait" opportunity, emphasizing that the current market may be overreacting to short-term sales data from the company, which still maintains leadership in the GLP-1 market despite guiding for potential negative or low single-digit sales growth in 2026 following strong performance in 2025.

πŸ“‰ Novo Nordisk trades at a 12x earnings multiple versus Eli Lilly's 26x–38x valuation.

πŸ’Š Novo holds an early lead in oral GLP-1 uptake with over 18,000 recent prescriptions.

πŸ” Some analysts favor Novo as an income play or short-term catch-up opportunity over Lilly.

πŸ“‰ Novo Nordisk (NVO) has declined roughly 68% from its mid-2024 highs near $127, while Eli Lilly (LLY) continues to trade at a premium.

πŸ’Š Data suggests a prescription uptake gap for oral GLP-1s, with Novo's pill garnering over 18,000 prescriptions in the second week versus 3,700 for Lilly's newly approved Fendayo.

πŸ“Š Novo Nordisk trades at approximately 12x earnings compared to Eli Lilly's 26x to 38x valuation multiple, making it appear undervalued relative to its rival.

πŸ’° Novo is projected to offer a 4% dividend yield and a 6.5%+ free cash flow yield in 2027, which appeals to income-focused investors despite lower growth forecasts.

πŸ“ˆ Eli Lilly reported Q1 2026 revenue of $19.8 billion with EPS of $8.55, though management recently raised its full-year revenue guidance.

⚠️ Novo Nordisk has lowered its sales growth guidance for 2026 to a -5% to -13% range after recording 10% constant-currency growth in 2025.

πŸ”„ CNBC's Fast Money panel recently pivoted their stance, arguing that NVO now offers a more compelling setup than the GLP-1 category leader LLY.

πŸ’Έ The performance gap between the two has narrowed significantly, with LLY turning $1 into $2.30 over three years while NVO only reached $0.48 in the same period.

πŸ•°οΈ One panelist characterized Novo as a "get paid to wait" story for investors willing to endure near-term weakness for long-term dividends.

πŸ€” Some analysts view Novo's current opportunity as a short-term trade or catch-up play rather than a full-blown stock re-rating turnaround.

πŸ‘€ An expert analyst who correctly predicted NVIDIA in 2010 recently released his top 10 stocks for 2026, and notably excluded Eli Lilly from the list.

πŸ“‰ Current price performance shows NVO down 18.08% year-to-date while LLY is down 20.66%, creating similar absolute declines but different relative valuations.

Bullish Signals
  • Eli Lilly raised its full-year revenue guidance to a range of $82.0–$85.0 billion, signaling strong management confidence and execution.
  • Lilly's Q1 2026 revenue reached an impressive $19.80 billion with EPS of $8.55, demonstrating robust financial performance despite market headwinds.
  • CEO David Ricks characterized the approval of oral GLP-1 Fendayo as a "key milestone," highlighting significant progress in expanding their drug delivery options.
  • The company recently reported strong quarterly results that overshadowed concerns regarding early prescription uptake for its new oral pill.
  • With shares trading at approximately 26x earnings, Lilly maintains a premium valuation that reflects continued market dominance and strong growth expectations.
  • Over the past three years, Eli Lilly has outperformed peers significantly, turning $1 into $2.30, demonstrating superior long-term shareholder returns.
Risk Factors
  • Novo Nordisk's shares have fallen approximately 68% from its mid-2024 highs, dropping from near $127 to recent levels around $40.
  • Lilly's newly approved oral GLP-1 drug, Fendayo, received only 3,700 prescriptions in its second week compared to over 18,000 for Novo Nordisk's competing oral pill, indicating a significant uptake gap.
  • Novo Nordisk is guiding for -5% to -13% sales growth in 2026 after posting 10% constant-currency growth in 2025, signaling near-term headwinds.
  • Despite recent price action convergence where both stocks are down roughly 18-20%, Novo Nordisk trades at a discounted valuation of roughly 12x earnings versus Lilly's premium multiple closer to 38x-40x.
  • Lilly turned $1 into $2.30 over the past three years, while Novo fell to just $0.48 over the same period, creating a substantial gap in total shareholder return that investors are now questioning.
  • One panelist described the current view on Novo Nordisk as merely a 'trade' or short-term catch-up rather than a sustained re-rating, suggesting limited long-term upside potential.
Bullish +75

Eli Lilly stock soars after Q1 earnings as revenue grows 56% on strength of GLP-1 drug sales

AI-generated analysis

Eli Lilly (LLY) stock surged nearly 10% on Thursday following the release of strong Q1 earnings, driven primarily by exceptional sales of its GLP-1 drugs, Zepbound and Mounjaro. These medications are used for weight management and diabetes, with Zepbound revenue climbing 80% year over year to $4.16 billion, while Mounjaro revenue jumped 125% to reach $8.66 billion. Despite facing lower prices for these drugs in the United States, robust demand allowed overall company revenue to grow by 56% year over year to $19.7 billion, with GLP-1 drugs now accounting for approximately two-thirds of Eli Lilly's total sales. The company highlighted a significant milestone achieved during the quarter: the FDA's approval of Foundayo, an oral pill version of its weight-loss drug. This development is considered a major tailwind as it offers convenience for patients who can take the medication at any time of day without restrictions on food or water intake. David Ricks, CEO of Eli Lilly, referred to this FDA approval as a "key milestone" in the company's growth trajectory. Despite the significant single-day gain, Eli Lilly shares remain down roughly 13% year to date, reflecting ongoing challenges in the sector. The stock has been weighed down by increasing competition within the weight-loss drug market and persistent pricing pressure on existing products. The strong quarterly performance underscores the continued market dominance of GLP-1 medications, yet investors are watching closely to see if the company can maintain growth momentum amid these external headwinds.

πŸ“ˆ LLY stock surged nearly 10% after Q1 earnings exceeded expectations.

πŸ’Š GLP-1 sales jumped 56% year-over-year to $19.7 billion total.

βœ” FDA approval of Foundayo pill boosts weight-loss drug accessibility.

⚠ Shares remain down 13% YTD amid pricing and competition issues.

🩺 Mounjaro treats diabetes, while Zepbound focuses on weight management.

πŸ“ˆ Eli Lilly (LLY) stock surged nearly 10% on Thursday following the release of its Q1 earnings report.

πŸ’Š Revenue from GLP-1 drugs Zepbound and Mounjaro drove overall company revenue up 56% year over year to $19.7 billion.

πŸ”Ό Zepbound revenue jumped 80% to $4.16 billion, while Mounjaro sales soared 125% to $8.66 billion.

πŸ’° Despite price reductions in the US market, strong demand resulted in GLP-1s accounting for roughly two-thirds of total sales.

βœ”οΈ A major positive catalyst was the FDA approval of Foundayo, a new oral pill version of the weight-loss drug.

πŸ• The new Foundayo pill can be taken any time of day without food or water restrictions, according to CEO David Ricks.

⚠️ Despite the recent rally, LLY shares remain down approximately 13% year-to-date due to competition and pricing pressures.

🩺 Zepbound is approved for weight management, while Mounjaro is used for diabetes treatment.

Bullish Signals
  • Eli Lilly stock surged nearly 10% on strong earnings.
  • Revenue grew 56% year over year to $19.7 billion.
  • Zepbound revenue rose 80% despite lower US prices.
  • Mounjaro revenue soared 125% driven by robust demand.
  • GLP-1 drugs now account for roughly two-thirds of sales.
  • FDA approved Foundayo, the only unrestricted GLP-1 pill.
  • Foundayo approval boosts weight-loss business and product pipeline.
Risk Factors
  • Stock down 13% ytd due to competition and pricing pressure.
  • Heavy reliance on GLP-1s creates concentration risk at two-thirds of sales.
  • Lower US prices for Zepbound/Mounjaro indicate potential margin compression.
  • 80% and 125% growth in key drugs highlights segment vulnerability.
Bullish Signals
  • Eli Lilly (LLY) stock soared nearly 10% on Thursday following strong quarterly earnings.
  • Revenue grew 56% year over year to $19.7 billion, driven by robust demand for GLP-1 drugs Zepbound and Mounjaro.
  • Zepbound revenue increased 80% year over year to $4.16 billion despite lower US prices.
  • Mounjaro revenue soared 125% year over year to $8.66 billion as demand continues to lift overall sales.
  • GLP-1 drugs now account for roughly two-thirds of Eli Lilly's total sales, indicating a dominant market position.
  • The FDA approved Foundayo, the only approved GLP-1 pill that can be taken any time of day without food or water restrictions.
  • Foundayo approval provides a significant tailwind to the company's weight-loss business and product pipeline.
Risk Factors
  • Despite record-breaking revenue growth, Eli Lilly's stock is down roughly 13% year-to-date due to intensifying competition and pricing pressure.
  • The strong financial performance relies heavily on GLP-1 drugs which now account for approximately two-thirds of the company's total sales, creating significant concentration risk.
  • Lower prices for Zepbound and Mounjaro in the US market were required to achieve revenue growth, indicating potential margin compression from pricing headwinds.
  • Zepbound revenues increased 80% year over year to $4.16 billion while Mounjaro soared 125% to $8.66 billion, highlighting vulnerability to any future slowdown in this dominant segment.
Somewhat Bullish +50

Who Benefits From Amazon Pharmacy Stocking Eli Lilly’s New Weight Loss Pill

AI-generated analysis

On April 9, 2026, Amazon announced that its pharmacy unit will begin stocking Eli Lilly's new GLP-1 weight-loss pill, Foundayo, at One Medical kiosks with same-day home delivery plans to reach 4,500 locales by the end of 2026. This expansion integrates Amazon Pharmacy as a key dispensing partner for LillyDirect, which began selling Foundayo directly to cash-pay customers at $149 per month for the lowest dose. The strategic move positions Eli Lilly as a primary beneficiary, with its GLP-1 portfolio generating $11.67 billion in Q4 2025 revenue alone through Zepbound and Mounjaro, contributing significantly to a full-year 2025 revenue of $65.18 billion that rose 44.7% year-over-year. Management projects Lilly's revenue could reach between $80 billion and $83 billion in 2026, while CEO David Ricks emphasized the company's ability to reach more patients through platforms like LillyDirect as it enters its 150th year. Several other companies face varying degrees of impact from this distribution shift. CVS Health benefits across its retail pharmacies, Caremark pharmacy benefit manager, and Aetna insurance operations, with same-store prescription volume growing 9.7% in Q4 2025 and pharmacy sub-segment revenue reaching $31.38 billion in the same quarter to help achieve its ambition of becoming the most trusted health care company in America. Novo Nordisk faces increased competitive pressure as Amazon Pharmacy adds Foundayo to its kiosks where Wegovy is already stocked; the company reported a 15% decline in U.S. operations in Q4 2025 and issued guidance for adjusted sales growth between -5% and -13% at constant exchange rates in 2026, though President Mike Doustdar remains encouraged by early uptake of the Wegovy pill launch. Viking Therapeutics lacks an approved product or current Amazon relationship but sees indirect benefits as clinical validation strengthens its investment case for Phase 3 asset VK2735 with over 4,500 patients enrolled. Amazon CEO Andy Jassy stated that while investing approximately $200 billion in capital expenditures in 2026 across areas like AI and robotics, the pharmacy business remains central to its strategy of reaching customers faster and more directly through Prime membership stickiness. Foundayo is particularly well-suited for this model as it requires no refrigeration compared to injectable competitors. Eli Lilly plans to support this scale with manufacturing expansion, including a $6 billion facility in Alabama and a $3 billion oral medicine facility in Europe. While Amazon builds recurring revenue from healthcare relationships and CVS maintains its role in processing insurance claims behind retail fronts, Novo Nordisk must navigate pricing headwinds in an increasingly competitive market where the pill format removes cold-chain barriers previously limiting kiosk access to weight-loss drugs.

πŸ“ˆ Amazon Pharmacy will stock Eli Lilly's GLP-1 pill Foundayo starting April 9, 2026.

πŸ’° LillyDirect prices Foundayo at $149/month lowest dose with Amazon dispensing support.

⚠️ Novo Nordisk faces competitive pressure as Wegovy shares Amazon kiosks with Foundayo.

πŸ“Š Lilly reported $11.67B Q4 2025 revenue from Zepbound and Mounjaro driving growth.

πŸš€ CVS Health benefits via Caremark insurance claims and retail pharmacy dispensing channels.

πŸ“ˆ Amazon Pharmacy will stock Eli Lilly's new GLP-1 pill Foundayo at One Medical kiosks starting April 9, 2026, with plans to expand to 4,500 locales by year-end.

πŸ’Š Foundayo is sold directly to patients through LillyDirect at $149 per month for the lowest dose, with Amazon acting as a key dispensing partner.

🏒 Eli Lilly stands as the clearest beneficiary due to direct revenue flow from Amazon Pharmacy filling prescriptions via the LillyDirect channel.

πŸ“‰ Novo Nordisk faces increased competitive pressure as its Wegovy pill now shares Amazon kiosks with Foundayo following recent market share losses.

πŸ’Ό CVS Health benefits across multiple arms including Caremark for insurance claims and retail pharmacies for dispensing existing scripts.

πŸš€ Viking Therapeutics stands to gain indirectly as a stronger GLP-1 market validates its pipeline asset VK2735 currently in Phase 3 trials.

πŸ“Š Lilly reported $11.67 billion combined revenue from Zepbound and Mounjaro in Q4 2025, driving full-year growth to $65.18 billion.

🀝 Amazon invested over $4 billion in 2025 to expand delivery options, with Foundayo's non-refrigerated pill format fitting the kiosk model.

πŸ’¬ Eli Lilly CEO David Ricks emphasized that deep pipelines and platforms like LillyDirect will expand their global health impact entering their 150th year.

🀝 Amazon CEO Andy Jassy highlighted a $200 billion capital expenditure expectation for 2026, positioning pharmacy within the broader thesis of faster customer reach.

⚠️ Novo Nordisk issued cautious 2026 guidance predicting adjusted sales growth between -5% and -13% due to pricing headwinds and competition.

🏭 Lilly is scaling manufacturing with a $6 billion facility in Alabama and a $3 billion oral medicine facility in Europe to support demand.

πŸ”¬ Viking Therapeutics CEO Brian Lian focused on clinical milestones rather than commercial distribution given its pre-revenue status.

πŸ’° Pharmacy sub-segment revenue for CVS grew 15.2% in Q4 2025 to $31.38 billion as same-store prescription volume accelerated by 9.7%.

🚚 Amazon's One Medical kiosk model is validated for future drug categories through every Foundayo prescription filled via the partnership.

Bullish Signals
  • Eli Lilly generated $11.67B quarterly revenue from Zepbound and Mounjaro in Q4 2025.
  • Full-year 2025 Eli Lilly revenue grew 44.7% to $65.18 billion.
  • Management raised full-year 2026 revenue guidance to $80-83 billion.
  • Eli Lilly invested in new $6B Alabama and $3B European manufacturing facilities.
  • Amazon Pharmacy serves nearly 100M customers with same-day delivery.
  • Amazon spent over $4 billion in 2025 on delivery options expansion.
  • Viking Therapeutics benefits from expanded GLP-1 market accessibility.
  • Novo Nordisk optimistic about US Wegovy pill launch in 2026.
Risk Factors
  • Novo Nordisk U.S. operations fell 15% in Q4 2025.
  • Novo Nordisk expects adjusted sales growth of βˆ’5% to βˆ’13% in 2026.
  • Viking Therapeutics lacks approved products and depends on future regulatory approval.
  • Lilly's manufacturing expansion requires $6B investment in Alabama.
  • Lilly's European facility requires $3B investment for oral medicine.
  • Amazon plans $200B capital expenditures in 2026, straining cash flow.
  • CVS revenue growth exposes it to Amazon competition risks.
  • LillyDirect sells at $149/month, limiting insurance coverage penetration.
Bullish Signals
  • Eli Lilly generated $11.67 billion in combined quarterly revenue from Zepbound ($4.26 billion) and Mounjaro ($7.41 billion) in Q4 2025, reflecting strong market uptake.
  • Full-year 2025 revenue for Eli Lilly reached $65.18 billion, representing a significant 44.7% year-over-year growth.
  • Management at Eli Lilly has raised full-year 2026 revenue guidance to a range of $80 billion to $83 billion, signaling strong confidence in future performance.
  • Lilly's manufacturing expansion includes major investments like a new $6 billion facility in Alabama and a $3 billion oral medicine facility in Europe to support global scale.
  • Amazon Pharmacy has expanded its reach to serve nearly 100 million customers with same-day delivery, creating deep recurring revenue opportunities through the healthcare channel.
  • Amazon invested over $4 billion in 2025 alone to triple its companywide delivery options, strengthening its healthcare integration strategy.
  • Viking Therapeutics sees indirect growth benefits as increased accessibility of GLP-1 drugs like Foundayo expands the total addressable market for its VK2735 pipeline.
  • Novo Nordisk expressed optimism about promising early uptake from the US launch of its Wegovy pill in 2026, despite broader market headwinds.
Risk Factors
  • Novo Nordisk's U.S. operations declined 15% in Q4 2025 due to lower realized prices and market share losses.
  • Novo Nordisk issued cautious 2026 guidance calling for adjusted sales growth of βˆ’5% to βˆ’13% at constant exchange rates amid intensifying competition.
  • Viking Therapeutics lacks both approved products and a direct Amazon Pharmacy relationship, relying entirely on future regulatory approval for revenue generation.
  • Lilly's manufacturing expansion requires significant capital allocation with $6 billion invested in an Alabama facility and $3 billion in a European oral medicine facility.
  • Amazon plans to invest approximately $200 billion in capital expenditures across the company in 2026, which may strain cash flow despite strong revenue growth.
  • Pharmacy sub-segment revenue growth of 15.2% for CVS reflects rising adoption but exposes the company to competitive pressures from Amazon's same-day delivery model.
  • Lilly's LillyDirect channel sells directly to cash-pay customers at $149 per month, potentially limiting payer relationships and insurance coverage penetration compared to injectables.
Bullish +75

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

AI-generated analysis

Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) reported contrasting quarterly results in early February that have widened the competitive gap between the two giants in the obesity drug market. Lilly's fourth-quarter revenue surged to $19.29 billion, representing a 42.6% year-over-year increase, driven almost exclusively by its tirzepatide franchise with Mounjaro revenue jumping 110% to $7.41 billion and Zepbound rising 123% to $4.26 billion. This growth occurred despite a realized price headwind where prices slipped while volume expanded 46%, whereas Novo Nordisk's Q4 revenue declined 7.6% year-over-year, with U.S. operations specifically falling 15%. Full-year sales in DKK for Novo grew 6.43%, but operating income slipped 0.53% as the company tightened costs to manage the decline. In response to pricing headwinds and increased competition, Novo Nordisk acknowledged that 2026 will face significant challenges in an increasingly competitive market. To stabilize its position, the Danish pharmaceutical company cut approximately 9,000 jobs and absorbed roughly $8 billion in one-off charges during 2025. CEO Mike Doustdar noted a shift in strategy towards a newly launched oral pill, Wegovy, which began distribution in January 2026 across over 70,000 pharmacies and is currently generating about 50,000 weekly prescriptions at a starter dose of $149 per month. Novo faces further structural pressure from its Most Favoured Nations agreement with the U.S. administration and impending semaglutide patent expiry in select international markets, which contributed to a diabetes value market share decline of 3.6 percentage points to 30.1%. Conversely, Lilly is leveraging superior weight loss efficacy and an advanced pipeline. Tirzepatide’s dual GIP/GLP-1 mechanism achieves roughly 20% body weight reduction in trials compared to approximately 14% for Novo's Wegovy. Lilly also possesses a robust oral pipeline with orforglipron submitted for approval in the U.S., Japan, and EU after demonstrating it outperformed oral semaglutide in head-to-head trials, and retatrutide, a triple agonist, which showed weight loss of up to 71.2 lbs in Phase 3. Additionally, Lilly is scaling manufacturing significantly with new facilities planned in Alabama, Pennsylvania, and Europe, backed by commitments to exceed $50 billion in U.S. manufacturing investment since 2020. Investors note that if Lilly receives orforglipron approval in the U.S. by mid-2026, it would enter the oral market with a product already proven superior to Novo's semaglutide equivalent. The disparity is reflected starkly in their valuations and stock performance, with Lilly trading at a 27x forward P/E compared to Novo Nordisk's 11x forward earnings over the past year, reflecting a one-year price gain of 27.65% for Lilly versus a 39.85% decline for Novo. While Lilly is viewed as executing at a high level with deep pipeline depth and manufacturing buildout, Novo's direction concerns analysts due to genuine structural concerns regarding pricing pressure and patent dynamics. Novo Nordisk still generates enormous cash flow and offers a dividend yield of 4.88%, which may appeal to value investors awaiting potential catalysts such as CagriSema efficacy data or Medicare coverage expansion for obesity drugs that could add roughly 15 million eligible patients to the market.

πŸ“ˆ Lilly Q4 revenue surged 42.6% to $19.3B, driven by weight loss drugs.

πŸ’° Novo Nordisk Q4 revenue fell 7.6% amid pricing pressures and job cuts.

πŸ’Š Lilly's tirzepatide outperforms Novo's Wegovy with higher weight loss potential.

πŸ“ˆ Eli Lilly reported $19.29 billion in Q4 revenue, representing a 42.6% year-over-year increase driven primarily by its weight loss franchise.

πŸ’° Mounjaro generated $7.41 billion in Q4 with an 110% surge, while Zepbound contributed $4.26 billion and grew 123%.

πŸš€ Lilly’s tirzepatide is driving volume growth of 46% despite a slip in realized prices due to market conditions.

πŸ“‰ Novo Nordisk saw Q4 revenue decline by 7.6%, with U.S. operations specifically falling 15% year-over-year.

πŸ”¨ Novo cut approximately 9,000 jobs and incurred $8 billion in one-off charges during 2025 to address declining sales.

πŸ’‰ Novo’s Wegovy injectable offers roughly 14% body weight reduction compared to Lilly’s tirzepatide at 20%.

πŸ“ Novo launched an oral Wegovy pill in January 2026, generating around 50,000 weekly prescriptions across 70,000 pharmacies.

πŸ’Š Lilly’s oral candidate orforglipron submitted for approval in the U.S., Japan, and EU following Phase 3 data outperforming oral semaglutide.

🧬 Retatrutide, Lilly's triple agonist, demonstrated up to 71.2 lbs of weight loss during Phase 3 trials.

🏭 Lilly is expanding manufacturing capacity in Alabama, Pennsylvania, and Europe with over $50 billion in U.S. investment commitments.

⚠️ Novo faces structural pricing pressures from the Most Favoured Nations agreement and impending patent expiries.

🩺 Novo’s diabetes market share declined 3.6 percentage points to 30.1% as competitors gain ground.

πŸ’° Lilly trades at a 27x forward P/E multiple compared to Novo Nordisk's 11x forward earnings multiple.

πŸ“‰ Novo Nordisk saw its stock price decline 39.85% over the past year while Lilly gained 27.65%.

πŸ₯ A Medicare coverage expansion could add roughly 15 million eligible patients to the obesity drug market in 2026.

πŸ’‘ Novo’s CagriSema is submitted to the FDA for weight management, awaiting differentiated efficacy data.

πŸ“‰ Lilly’s pipeline depth and manufacturing scale provide a growth edge despite its higher premium valuation.

πŸ‘€ Market attention will focus on whether orforglipron approval by mid-2026 undercuts Novo's newly launched oral pill.

πŸ’Ό Novo Nordisk generates enormous cash flow but faces multi-year headwinds from pricing and patent dynamics.

🏦 Lilly trades at a 4x higher forward multiple, reflecting investors' confidence in its execution and growth trajectory.

πŸ“‰ Novo’s dividend yield stands at 4.88%, potentially appealing to value investors waiting for clinical or coverage catalysts.

Bullish Signals
  • Q4 revenue hit $19.29B, up 42.6% YoY driven by tirzepatide.
  • Mounjaro Q4 sales reached $7.41B (up 110%), Zepbound added $4.26B (up 123%).
  • Tirzepatide achieves ~20% weight loss, beating Novo's Wegovy (~14%).
  • Lilly expanding manufacturing across Alabama, Pennsylvania, and Europe.
  • Orforglipron approved in U.S., Japan, EU; beat oral semaglutide head-to-head.
  • Retatrutide lost up to 71.2 lbs in Phase 3 trials.
  • Orforglipron oral approval expected mid-2026 after beating oral semaglutide.
  • Lilly trades at 27x forward P/E, reflecting strong growth momentum.
  • Lilly up 27.65% vs. Novo down 39.85% over the past year.
Risk Factors
  • Revenue down 7.6% YoY; U.S. fell 15%.
  • Operating income slipped 0.53% amid cost pressures.
  • CEO warns of 2026 pricing headwinds in competition.
  • Cut 9,000 jobs; absorbed $8B charges in 2025.
  • Faces structural U.S. pricing pressure and patent expiry.
  • Diabetes market share down 3.6 points to 30.1%.
  • Stock down 39.85% YoY with forward P/E of 11x.
  • Competitor oral tirzepatide outperforms, threatening Novo's launch.
Bullish Signals
  • Liily's fourth quarter revenue reached $19.29 billion, representing a 42.6% year-over-year increase driven by its strong tirzepatide franchise.
  • Mounjaro generated $7.41 billion in Q4 (up 110%), while Zepbound added $4.26 billion (up 123%), demonstrating powerful growth from two core products.
  • Tirzepatide's dual GIP/GLP-1 mechanism delivers roughly 20% body weight reduction in trials, outperforming Novo's Wegovy at approximately 14%.
  • Lilly is building manufacturing at scale with new facilities in Alabama, Pennsylvania, and Europe, alongside commitments to exceed $50 billion in U.S. manufacturing investment since 2020.
  • Orforglipron has been submitted for approval in the U.S., Japan, and EU, with Phase 3 data showing it outperformed oral semaglutide in a head-to-head trial.
  • Retatrutide, a triple agonist developed by Lilly, showed weight loss of up to 71.2 lbs in Phase 3 trials, showcasing deep pipeline efficacy.
  • If Lilly receives orforglipron approval in the U.S. by mid-2026, it enters the oral market with a product that has already beaten oral semaglutide in a head-to-head trial.
  • Lilly trades at a 27x forward P/E, reflecting strong growth momentum and a business executing at a high level.
  • Lilly's one-year price gain of 27.65% reflects a business executing at a high level while Novo's 39.85% one-year decline reflects genuine structural concern.
Risk Factors
  • Novo Nordisk's fourth quarter revenue declined 7.6% year-over-year, with U.S. operations falling an even steeper 15%.
  • Operating income slipped 0.53% as costs tightened, indicating underlying profitability pressures despite full-year sales growth in DKK.
  • CEO Mike Doustdar warned that in 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market.
  • The company cut roughly 9,000 jobs and absorbed approximately $8 billion in one-off charges during 2025, signaling significant cost reduction efforts.
  • Novo faces structural pricing pressure from its Most Favoured Nations agreement with the U.S. administration and semaglutide patent expiry in select international markets.
  • The company's diabetes value market share declined 3.6 percentage points to 30.1%, reflecting competitive erosion in its core segment.
  • Novo Nordisk's stock is down 39.85% over the past year, with a forward P/E of 11x reflecting genuine structural concern compared to competitors.
  • Lilly's new oral tirzepatide (orforglipron) has already outperformed oral semaglutide in head-to-head trials, potentially putting Novo's oral Wegovy pill under immediate competitive pressure upon its January 2026 launch.
Bullish +75

Amazon expands access to weight-loss pill with kiosks, same-day delivery

AI-generated analysis

Amazon is significantly expanding access to Eli Lilly’s newly approved weight-loss pill, known as Foundayo, by integrating it into its pharmacy operations and logistical network. According to CNBC, Amazon Pharmacy will begin stocking the medication at kiosks located within select One Medical primary care clinics, while also enabling same-day delivery for customers in specific regions. This strategic expansion leverages the pill's unique advantage over injectable alternatives: it does not require refrigeration. Tanvi Patel, vice president at Amazon Pharmacy, explained that this lack of cold storage needs allows the medication to be safely stored and dispensed directly from kiosks, thereby facilitating broader access for patients. The initiative builds upon Amazon’s existing healthcare efforts, which include delivering GLP-1 medications since 2021 and stocking Novo Nordisk’s oral Wegovy pill at select kiosks earlier in the year. Currently, approximately half of U.S. customers have access to same-day delivery through Amazon Pharmacy, with a stated plan to expand this reach. All customers remain eligible for medication delivery within four days. Eli Lilly launched Foundayo recently via its direct-to-consumer platform, LillyDirect, with pricing starting at $149 per month for the lowest dose for cash-paying customers; Amazon Pharmacy will handle prescription fulfillment and partner with organizations like WeightWatchers for delivery options. Amazon introduced its pharmacy kiosks previously to improve medication access and reduce shipping costs, noting that this new rollout is subject to state regulations, with current operations primarily focused on California. Tanvi Patel indicated that kiosk locations are planned to expand beyond the state as regulatory frameworks allow. This move represents a key component of Amazon’s broader push to grow its healthcare footprint and delivery services, including investments aimed at accelerating delivery capabilities in rural and underserved areas. The collaboration highlights an increasing focus on convenient oral therapies that bypass the complexities associated with storing injectable GLP-1 drugs.

πŸ’Š Amazon Pharmacy adds Eli Lilly's Foundayo GLP-1 pill to clinic kiosks by 2026.

πŸ“¦ No refrigeration needed for this oral weight-loss medication compared to injectable alternatives.

🚚 Same-day delivery expands in select areas with all prescriptions delivered within four days.

πŸ“¦ Amazon Pharmacy will stock Eli Lilly's new Foundayo GLP-1 pill at clinic kiosks starting in 2026.

πŸ’Š The oral medication offers storage advantages over injectable drugs by not requiring refrigeration.

🚚 Same-day delivery will be available in select areas, expanding beyond the current half of U.S. customers.

⏳ All prescription medications can be delivered within four days regardless of delivery speed tier.

🀝 Amazon Pharmacy is already filling prescriptions for Foundayo launched on Eli Lilly's direct-to-consumer platform.

πŸ₯ The rollout includes kiosks inside One Medical primary care clinics across selected locations.

πŸ“ Kiosk availability beyond California depends on state regulations and compliance requirements.

πŸ’΅ Prices for the lowest dose of Foundayo start at $149 per month for cash-paying customers via LillyDirect.

πŸ”™ Amazon began delivering oral Wegovy from Novo Nordisk earlier this year at select kiosks.

🚁 This initiative supports Amazon's broader multibillion-dollar investment to expand delivery in rural and underserved areas.

🌐 The strategy aims to improve access to common medications while reducing shipping costs through localized kiosk distribution.

Bullish Signals
  • Amazon expands access to Eli Lilly's Foundayo GLP-1 pill via One Medical kiosks and same-day delivery.
  • The pill requires no refrigeration, simplifying storage compared to injectable drugs.
  • Amazon will extend same-day medication delivery beyond its current half of U.S. customers.
  • All customers receive medication within four days through Amazon Pharmacy nationwide.
  • Amazon has delivered GLP-1 medications since 2021 and stocks Novo Nordisk's Wegovy at select kiosks.
  • Amazon Pharmacy fulfills LillyDirect prescriptions starting at $149/month for the lowest dose.
  • Amazon is investing multibillions to expand healthcare delivery in rural and underserved areas.
Risk Factors
  • Amazon's Eli Lilly drug deal faces regulatory scrutiny.
  • Kiosk model limited by state regulations outside California.
  • Same-day delivery serves only half of U.S. customers.
Bullish Signals
  • Amazon is expanding access to Eli Lilly's new GLP-1 weight-loss pill, Foundayo, by stocking it at clinics' One Medical kiosks and offering same-day delivery.
  • The pill does not require refrigeration, which simplifies storage and dispensing compared to injectable drugs and supports broader availability via kiosks.
  • Amazon plans to expand its same-day delivery reach for medications beyond the current half of U.S. customers it already serves.
  • All customers can receive medication within four days through Amazon Pharmacy, even in areas where same-day delivery isn't yet available.
  • Amazon has been delivering GLP-1 medications since 2021 and has begun stocking Novo Nordisk's oral Wegovy pill at select kiosks earlier this year.
  • Amazon Pharmacy fulfills prescriptions from Eli Lilly's direct-to-consumer platform, LillyDirect, making the medication accessible starting at $149 per month for the lowest dose.
  • The initiative is part of a multibillion-dollar investment by Amazon to expand its healthcare and delivery footprint, particularly in rural and underserved areas.
Risk Factors
  • Amazon's expansion into Eli Lilly's Foundayo drug may trigger regulatory scrutiny given the company's history with pharmaceuticals.
  • The kiosk model relies on state regulations that could restrict future expansion beyond California.
  • Same-day delivery remains limited to only half of U.S. customers, potentially reducing market penetration compared to competitors.
Neutral 0

Eli Lilly (LLY) Laps the Stock Market: Here's Why - Yahoo Finance

AI-generated analysis

Eli Lilly and Company (LLY) shares closed the session up 1.82% at $1,008.39, outperforming the S&P 500's gain of 0.83%, the Dow's 0.5%, and the Nasdaq's 1.38%. However, despite this daily gain, the stock has depreciated by 6.41% over the past month, underperforming both the Medical sector's loss of 3.46% and the S&P 500's loss of 2.65% during that period. The company is scheduled to release its earnings report on April 30, 2026, with analysts expecting earnings per share of $7.5, representing a year-over-year growth rate of 124.55%. For the full year, consensus estimates project earnings of $34.16 per share and revenue of $81.93 billion, which would reflect increases of 41.1% and 25.7%, respectively, from the prior year. The Q1 revenue is expected to reach $17.66 billion, a significant 38.75% increase from the previous quarter. Recent adjustments to analyst estimates show a 0.24% upward shift in consensus EPS over the past month, yet LLY currently holds a Zacks Rank of #3 (Hold) based on these revisions and business trends. In terms of valuation, Eli Lilly trades at a forward price-to-earnings ratio of 29 compared to an industry average of 15.83, indicating it is priced at a premium relative to its peers. The stock also holds a PEG ratio of 1.17 against an industry average of 2.24, suggesting better growth-adjusted value by that metric. The Large Cap Pharmaceuticals industry, in which LLY operates, holds a Zacks Industry Rank of 200 and is situated in the bottom 19% of all tracked industries, where research indicates that top-rated industries typically outperform the bottom half by a factor of 2 to 1. Investors are encouraged to monitor upcoming earnings and estimate revisions as these metrics have historically shown a direct relationship with future stock price performance.

πŸ“ˆ LLY shares closed up 1.82% at $1,008.39, outperforming the S&P 500.

πŸ’° Analysts project quarterly EPS of $7.5 and revenue of $17.66 billion.

⚠️ Stock trades at a high Forward P/E of 29 vs industry average of 15.83.

πŸ“ˆ Eli Lilly shares closed up 1.82% at $1,008.39, outperforming the S&P 500's 0.83% gain.

πŸ“‰ Despite recent gains, LLY stock has depreciated 6.41% over the past month.

πŸ—“οΈ The company is scheduled to release its quarterly earnings report on April 30, 2026.

πŸ’° Analysts project upcoming quarterly EPS of $7.5, representing a 124.55% year-over-year increase.

πŸ’΅ Expected quarterly revenue is forecasted at $17.66 billion, up 38.75% from the prior quarter.

πŸ“Š Full-year earnings consensus estimates total $34.16 per share with a 41.1% year-over-year rise.

πŸ“‰ Full-year revenue is projected at $81.93 billion, marking a 25.7% increase from last year.

πŸ“‰ The Zacks Consensus EPS estimate has shifted 0.24% upward recently for the company.

βš–οΈ Eli Lilly currently holds a Zacks Rank of #3 (Hold) according to the investment model.

πŸ’° LLY trades at a Forward P/E ratio of 29, significantly higher than the industry average of 15.83.

πŸ“ˆ The stock's PEG ratio is 1.17, which is lower than the Large Cap Pharmaceuticals industry average of 2.24.

🏭 The company belongs to the Medical sector, specifically within the Large Cap Pharmaceuticals industry.

πŸ“‰ This industry group ranks #200 and sits in the bottom 19% echelon of all industries tracked.

πŸ“ˆ Top-rated industries historically outperform the bottom half by a factor of 2 to 1.

⚠️ Investors are advised to monitor analyst estimate revisions as they correlate with stock price performance.

Bullish Signals
  • Shares rose 1.82% to $1,008.39, outpacing S&P 500's 0.83% gain.
  • Analysts project 124.55% earnings growth with quarterly EPS of $7.5.
  • Full-year consensus EPS forecast reaches $34.16, up 41.1% from prior year.
  • Projected annual revenue hits $81.93 billion, a 25.7% increase.
  • PEG ratio of 1.17 is below industry average of 2.24, showing value.
  • Consensus EPS estimate increased 0.24% recently amid positive analyst adjustments.
Risk Factors
  • Shares down 6.41% this month, underperforming sector and index.
  • Forward P/E of 29 is near double the industry average of 15.83.
  • High P/E relative to peers creates valuation risk despite neutral PEG.
  • Zacks Rank #3 hold rating limits strong buy opportunity.
  • Pharma industry ranks bottom 19% among all 250+ sectors.
Bullish Signals
  • Eli Lilly shares were up +1.82% at $1,008.39, outpacing the S&P 500's daily gain of 0.83%.
  • Analysts expect year-over-year earnings growth of 124.55%, with quarterly EPS estimated at $7.5.
  • Full-year Zacks Consensus Estimates project earnings of $34.16 per share, representing a +41.1% change from the prior year.
  • The company's projected full-year revenue of $81.93 billion represents a +25.7% increase from the prior year.
  • Eli Lilly is currently trading with a PEG ratio of 1.17, which is significantly lower than the industry average of 2.24, indicating value relative to growth.
  • The Zacks Consensus EPS estimate has shifted 0.24% upward recently, reflecting positive adjustments in analyst expectations.
Risk Factors
  • Eli Lilly's shares have depreciated by 6.41% over the past month, underperforming both the Medical sector (down 3.46%) and the S&P 500 (down 2.65%), indicating relative weakness despite positive market movements.
  • The stock is trading at a Forward P/E ratio of 29 compared to the industry average of 15.83, suggesting it is valued at a significant premium that could limit upside potential.
  • Eli Lilly's PEG ratio stands at 1.17 versus an industry average of 2.24, though this metric alone is neutral; however, the high P/E relative to peers remains a valuation risk.
  • The stock currently holds a Zacks Rank of #3 (Hold), indicating the analysis does not rate it as a strong buy opportunity at this time.
  • The Large Cap Pharmaceuticals industry ranks in the bottom 19% echelons among all 250+ industries, with top-rated sectors historically outperforming by a factor of 2 to 1, suggesting potential sector headwinds.